UBS Downgrades CVS Health to Neutral, Lowers Price Target to $60
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Kevin Caliendo downgraded CVS Health (NYSE:CVS) from Buy to Neutral and reduced the price target from $85 to $60, indicating a more cautious outlook on the company's stock.

May 02, 2024 | 1:16 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
UBS analyst Kevin Caliendo downgraded CVS Health from Buy to Neutral and lowered the price target from $85 to $60.
The downgrade by UBS from Buy to Neutral suggests a less optimistic view on CVS Health's future stock performance, potentially due to underlying challenges or market conditions. The significant reduction in the price target from $85 to $60 further underscores a cautious or bearish outlook, which could influence investor sentiment and lead to a short-term decrease in stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100